405 related articles for article (PubMed ID: 34011395)
1. Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance.
Li GH; Qu Q; Qi TT; Teng XQ; Zhu HH; Wang JJ; Lu Q; Qu J
J Exp Clin Cancer Res; 2021 May; 40(1):174. PubMed ID: 34011395
[TBL] [Abstract][Full Text] [Related]
2. Super-Enhancer-Driven Transcriptional Dependencies in Cancer.
Sengupta S; George RE
Trends Cancer; 2017 Apr; 3(4):269-281. PubMed ID: 28718439
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.
Shang S; Yang J; Jazaeri AA; Duval AJ; Tufan T; Lopes Fischer N; Benamar M; Guessous F; Lee I; Campbell RM; Ebert PJ; Abbas T; Landen CN; Difeo A; Scacheri PC; Adli M
Cancer Res; 2019 Sep; 79(18):4599-4611. PubMed ID: 31358529
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of super enhancer-derived noncoding RNAs in human cancer.
Wang Y; Nie H; He X; Liao Z; Zhou Y; Zhou J; Ou C
Theranostics; 2020; 10(24):11049-11062. PubMed ID: 33042269
[TBL] [Abstract][Full Text] [Related]
5. Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC.
Bao J; Li M; Liang S; Yang Y; Wu J; Zou Q; Fang S; Chen S; Guo L
BMC Med Genomics; 2019 May; 12(1):67. PubMed ID: 31118037
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Adv Clin Chem; 2020; 94():219-259. PubMed ID: 31952572
[TBL] [Abstract][Full Text] [Related]
7. Super-enhancers: A new frontier for glioma treatment.
Cheng M; Zhang ZW; Ji XH; Xu Y; Bian E; Zhao B
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188353. PubMed ID: 32112817
[TBL] [Abstract][Full Text] [Related]
8. The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.
Senthebane DA; Rowe A; Thomford NE; Shipanga H; Munro D; Mazeedi MAMA; Almazyadi HAM; Kallmeyer K; Dandara C; Pepper MS; Parker MI; Dzobo K
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28754000
[TBL] [Abstract][Full Text] [Related]
9. Potential roles of exosome non‑coding RNAs in cancer chemoresistance (Review).
Wang Y; Liu Q; Wang F
Oncol Rep; 2021 Feb; 45(2):439-447. PubMed ID: 33416168
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance.
Fatma H; Maurya SK; Siddique HR
Semin Cancer Biol; 2022 Aug; 83():166-176. PubMed ID: 33220458
[TBL] [Abstract][Full Text] [Related]
11. Long Noncoding RNA
Chen X; Xie R; Gu P; Huang M; Han J; Dong W; Xie W; Wang B; He W; Zhong G; Chen Z; Huang J; Lin T
Clin Cancer Res; 2019 Feb; 25(4):1389-1403. PubMed ID: 30397178
[TBL] [Abstract][Full Text] [Related]
12. Super-enhancers in cancer.
Thandapani P
Pharmacol Ther; 2019 Jul; 199():129-138. PubMed ID: 30885876
[TBL] [Abstract][Full Text] [Related]
13. The role of long non-coding RNAs in mediating chemoresistance by modulating autophagy in cancer.
Jin KT; Lu ZB; Lv JQ; Zhang JG
RNA Biol; 2020 Dec; 17(12):1727-1740. PubMed ID: 32129701
[TBL] [Abstract][Full Text] [Related]
14. Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies.
Dębek S; Juszczyński P
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188697. PubMed ID: 35150791
[TBL] [Abstract][Full Text] [Related]
15. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
16. DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network.
Hamdan FH; Johnsen SA
Proc Natl Acad Sci U S A; 2018 Dec; 115(52):E12343-E12352. PubMed ID: 30541891
[TBL] [Abstract][Full Text] [Related]
17. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
Capula M; Perán M; Xu G; Donati V; Yee D; Gregori A; Assaraf YG; Giovannetti E; Deng D
Drug Resist Updat; 2022 Sep; 64():100864. PubMed ID: 36115181
[TBL] [Abstract][Full Text] [Related]
18. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
[TBL] [Abstract][Full Text] [Related]
19. NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer.
Di Benedetto C; Oh J; Choudhery Z; Shi W; Valdes G; Betancur P
BMC Cancer; 2022 Oct; 22(1):1056. PubMed ID: 36224576
[TBL] [Abstract][Full Text] [Related]
20. Super-enhancers complexes zoom in transcription in cancer.
Wang M; Chen Q; Wang S; Xie H; Liu J; Huang R; Xiang Y; Jiang Y; Tian D; Bian E
J Exp Clin Cancer Res; 2023 Jul; 42(1):183. PubMed ID: 37501079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
